THE CORRELATION BETWEEN ALZHEIMER’S DISEASE CLINICAL FEATURES AND MRI OBSERVATIONS
Keywords:
Alzheimer’s disease, MRI, cognitive decline, neurodegeneration, brain atrophy, beta-amyloid, cognitive reserve, gender differences.Abstract
This article analyzes the correlation between the clinical features of Alzheimer's disease (AD) and magnetic resonance imaging (MRI) observations. Alzheimer's disease is a globally prevalent neurodegenerative disorder characterized by the accumulation of extracellular beta-amyloid plaques, intracellular neurofibrillary tangles of TAU protein, and progressive cognitive decline. The study explores key factors influencing disease progression, including age, genetics, lifestyle, and gender differences. Notably, the higher lifetime risk for women and the impact of educational background on cognitive reserve are highlighted. The research aims to evaluate the potential for early diagnosis by examining how structural brain changes and atrophy detected via MRI correlate with observed clinical symptoms.
References
References.Prince, M., Wimo, A., Guerchet, M., Ali, G.-C., Wu, Y.-T., & Prina, M. (2015). World Alzheimer Report 2015: The Global Impact of Dementia. Alzheimer’s Disease International. https://www.alz.co.uk/research/world-report-2015
Alzheimer’s Association. (2023). 2023 Alzheimer’s Disease Facts and Figures. Alzheimer’s & Dementia, 19(4), 1598–1695. https://www.alz.org/alzheimers-dementia/facts-figures
National Institute on Aging (NIA). (2022). Alzheimer’s Disease Fact Sheet. U.S. Department of Health & Human Services. https://www.nia.nih.gov/health/alzheimers
Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., … & Mukadam, N. (2020). Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. The Lancet, 396(10248), 413–446. https://doi.org/10.1016/S0140-6736(20)30367-6
Reitz, C., Brayne, C., & Mayeux, R. (2011). Epidemiology of Alzheimer disease. Nature Reviews Neurology, 7(3), 137–152. https://doi.org/10.1038/nrneurol.2011.2
Cummings, J., Lee, G., Ritter, A., & Zhong, K. (2018). Alzheimer’s disease drug development pipeline: 2018. Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 4, 195–214. https://doi.org/10.1016/j.trci.2018.03.006
Petersen, R.C., Roberts, R.O., Knopman, D.S., Boeve, B.F., Geda, Y.E., Ivnik, R.J., … & Jack, C.R. (2009). Mild cognitive impairment: ten years later. Archives of Neurology, 66(12), 1447–1455. https://doi.org/10.1001/archneurol.2009.266
Jack, C.R., Bennett, D.A., Blennow, K., Carrillo, M.C., Dunn, B., Haeberlein, S.B., … & Silverberg, N. (2018). NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimer’s & Dementia, 14(4), 535–562. https://doi.org/10.1016/j.jalz.2018.02.018
Scheltens, P., Blennow, K., Breteler, M.M.B., de Strooper, B., Frisoni, G.B., Salloway, S., & Van der Flier, W.M. (2016). Alzheimer’s disease. The Lancet, 388(10043), 505–517. https://doi.org/10.1016/S0140-6736(15)01124-1
Bateman, R.J., Xiong, C., Benzinger, T.L., Fagan, A.M., Goate, A., Fox, N.C., … & Morris, J.C. (2012). Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. New England Journal of Medicine, 367, 795–804. https://doi.org/10.1056/NEJMoa1202753
